Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study by Laura S. Puuniemi, Sanna M. E. Iivanainen, Martti Arffman, Riitta L. Kaarteenaho, Jussi P. Koivunen

Subjects: “…EGFR TKI…”
Get full text

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer by Azhar Ali, Elena Levantini, Jun Ting Teo, Julian Goggi, John G Clohessy, Chan Shuo Wu, Leilei Chen, Henry Yang, Indira Krishnan, Olivier Kocher, Junyan Zhang, Ross A Soo, Kishore Bhakoo, Tan Min Chin, Daniel G Tenen

Subjects: Get full text

Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance by Linjuan Wang, Yue Qiu, Xiang Huang, Shimei Zhang, Min Zhao, Qiufang Chen

Subjects: Get full text

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC by Yingqi Xu, Yidan Zhang, Hongping Jin, Hua Zhong, Jianlin Xu, Yuqing Lou, Runbo Zhong

Subjects: Get full text

Survival Outcomes in EGFR‐Mutant Non‐Small Cell Lung Cancer With Brain Metastases: Kaplan–Meier and Cox Regression Analyses Across Treatment Stages by Haoran Qi, Qiang Qiao, Xiaorong Sun, Ligang Xing

Subjects: Get full text

Recent Advances in the Use of <i>Ganoderma lucidum</i> and <i>Coriolus versicolor</i> Mushrooms to Enhance the Anticancer Efficacy of EGFR-Targeted Drugs in Lung Cancer by Hang Zhang, Longling Wang, Yuet Wa Chan, William C. Cho, Zhong Zuo, Kenneth K. W. To

Subjects: “…EGFR-TKI…”
Get full text

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer by Yuanzhou Zhang, Xiaojun Zhang, Xupeng Yang, Xingshi Chen, Yuehong Wang, Jingying Hu, Rui Liu, Xiaoying Luo

Subjects: Get full text

Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer by Yuhong Ma, Feng Zhang, Jin Li, Juan Li, Yanhua Li

Subjects: “…EGFR-TKI resistance…”
Get full text

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study by Yin Pan, Meichen Li, Mingjie Yu, Jing Chen, Hui Yu, Kaijing Liu, Likun Chen

Subjects: Get full text

Identification of expression profiles and transcription factors during EGFR‐TKI acquired resistance in LUAD by Lili Feng, Cenzhu Wang, Jiawen Chen, Chenyue Tao, Liuliu Zhang, Luojing Zhou

Subjects: Get full text

EMP3 is upregulated upon epithelial–mesenchymal transition and contributes to EGFR–tyrosine kinase inhibitor resistance in lung adenocarcinoma by Chunyan Wang, Mengting Xiong, Yifei Zhu, Kun Li, Jian Ni

Subjects: Get full text

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis by Shang‐Gin Wu, Chao‐Chi Ho, James Chih‐Hsin Yang, Shu‐Han Yu, Yen‐Feng Lin, Shu‐Chin Lin, Bin‐Chi Liao, Ching‐Yao Yang, Yen‐Ting Lin, Chong‐Jen Yu, Ya‐Ting Chuang, Wei‐Yu Liao, Kah Yi Yap, Weng Si Kou, Jin‐Yuan Shih

Subjects: Get full text

The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia by Elisna Syahruddin, Noni Novisari Soeroso, Fannie Rizki Ananda, Laksmi Wulandari, Ana Rima Setijadi, Sabrina Ermayanti, Suryanti Dwi Pratiwi, Andreas Infianto, Novita Andayani, Sri Melati Munir, Avissena Dutha Pratama, Ida Ayu Jasminarti Dwi Kusumawardani, Haryati Haryati, Natalie Duyen, Muhammad Alfin Hanif, Darren Wan-Teck Lim

Subjects: Get full text

CircSPINT2 confers sensitivity to osimertinib via hsa-miR-1296-3p/RBP1 axis and inhibits NSCLC progression by Nalini Devi Verusingam, Aliaksandr A. Yarmishyn, Min-Long Tsai, Ping-Hsing Tsai, Yi-Chen Chen, Chih-Ling Yeh, Soon-Keng Cheong, Po-Kuei Hsu, Shih-Hwa Chiou, Alan Han-Kiat Ong, Mong-Lien Wang

Subjects: “…EGFR-TKI…”
Get full text

HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells by Hanbing Lyu, Akihiko Ishimura, Ryusuke Suzuki, Khurelsukh Buyanbat, Gerelsuren Batbayar, Makiko Meguro-Horike, Shin-ichi Horike, Seiji Yano, Takeshi Suzuki

Subjects: Get full text

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma by E. V. Levchenko, F. V. Moiseenko, S. V. Orlov, E. N. Imyanitov, A. E. Mikhnin, M. L. Gelfond, E. N. Slugin, S. M. Ergnyan, N. E. Levchenko, A. S. Zhabina, A. M. Ulitin, O. Yu. Mamontov, O. O. Lopushanskaya, E. V. Artemeva, A. I. Murtazin, V. I. Shabinskaya

Subjects: Get full text

Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI by Yiming ZENG, Wenfeng FANG, Li ZHANG

Subjects: Get full text

Integration of continuous lumbar drainage and third-generation EGFR-TKI in managing leptomeningeal metastasis-induced life-threatening intracranial hypertension: a case report by Lei Wang, Lei Wang, Nianjun Ren, Zhi Tang, Rui Wang, Zhengwen He

Subjects: Get full text

Case Report: Osimertinib-induced acute interstitial lung disease by Zhiwu Lin, Liang Wu, Yang Yu, Jiudong Jiang, Yanchun Yang, Guibao Xiao

Subjects: Get full text

Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment by Rui FAN, Yonghui WU, Zhan GU, Yanbin PENG, Lixin WANG

Subjects: Get full text